[go: up one dir, main page]

AR083208A1 - Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion - Google Patents

Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion

Info

Publication number
AR083208A1
AR083208A1 ARP110103586A ARP110103586A AR083208A1 AR 083208 A1 AR083208 A1 AR 083208A1 AR P110103586 A ARP110103586 A AR P110103586A AR P110103586 A ARP110103586 A AR P110103586A AR 083208 A1 AR083208 A1 AR 083208A1
Authority
AR
Argentina
Prior art keywords
inhalation
dry powder
powder formulations
magnesium estearate
hydrolysis
Prior art date
Application number
ARP110103586A
Other languages
English (en)
Inventor
Daniela Cocconi
Alberi Massimiliano Dagli
Andrea Busca
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR083208A1 publication Critical patent/AR083208A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de estearato de magnesio en formulación en polvo para inhalación que comprende partículas de vehículo para inhibir o reducir la degradación química de un ingrediente activo que porta un grupo susceptible de hidrólisis. Una formulación farmacéutica en forma de polvo seco para inhalación que comprende (a) un vehículo, (b) estearato de magnesio, y c) una sustancia ingrediente activo susceptible de hidrólisis.
ARP110103586A 2010-09-30 2011-09-29 Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion AR083208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10183018 2010-09-30

Publications (1)

Publication Number Publication Date
AR083208A1 true AR083208A1 (es) 2013-02-06

Family

ID=43618674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103586A AR083208A1 (es) 2010-09-30 2011-09-29 Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion

Country Status (12)

Country Link
US (3) US20120082727A1 (es)
EP (1) EP2621494B1 (es)
KR (2) KR20140005150A (es)
CN (1) CN103298470B (es)
AR (1) AR083208A1 (es)
BR (1) BR112013007022B1 (es)
CA (1) CA2813096C (es)
ES (1) ES2704688T3 (es)
PL (1) PL2621494T3 (es)
RU (1) RU2580890C2 (es)
TR (1) TR201901644T4 (es)
WO (1) WO2012041717A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN104284679B (zh) 2012-03-13 2017-08-04 瑞斯比维特有限公司 药物制剂
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP2016534063A (ja) * 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
JP2019524865A (ja) 2016-08-31 2019-09-05 ザ ジェネラル ホスピタル コーポレイション 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2023224577A1 (en) * 2022-05-18 2023-11-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising micronized human insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2192866T3 (es) * 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
AU3409399A (en) 1999-03-05 2000-09-28 Chiesi Farmaceutici S.P.A. Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK1658872T4 (da) 2002-07-31 2019-11-11 Chiesi Farm Spa Pulverinhalator
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US7590021B2 (en) 2007-07-26 2009-09-15 Qualcomm Incorporated System and method to reduce dynamic RAM power consumption via the use of valid data indicators
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) * 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
WO2012041717A1 (en) 2012-04-05
EP2621494A1 (en) 2013-08-07
US20150320691A1 (en) 2015-11-12
KR101886987B1 (ko) 2018-08-08
ES2704688T3 (es) 2019-03-19
US20180133161A1 (en) 2018-05-17
HK1187822A1 (en) 2014-04-17
RU2013113965A (ru) 2014-10-10
US20120082727A1 (en) 2012-04-05
CN103298470A (zh) 2013-09-11
EP2621494B1 (en) 2018-11-07
PL2621494T3 (pl) 2019-04-30
CA2813096A1 (en) 2012-04-05
CA2813096C (en) 2019-10-29
BR112013007022A2 (pt) 2016-06-14
BR112013007022B1 (pt) 2019-10-15
RU2580890C2 (ru) 2016-04-10
TR201901644T4 (tr) 2019-02-21
KR20140005150A (ko) 2014-01-14
CN103298470B (zh) 2015-06-17
KR20170118231A (ko) 2017-10-24

Similar Documents

Publication Publication Date Title
AR083208A1 (es) Uso de estearato de magnesio en formulaciones de polvo seco para inhalacion
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
MX382405B (es) Método para suministrar un agente activo.
EP3216448B8 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
CL2014002283A1 (es) Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
WO2013114371A8 (en) Dry powder formulations of dnase i
PE20150668A1 (es) Formulaciones farmaceuticas topicas no acuosas
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CY1120684T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
WO2010021607A3 (en) Pharmaceutical formulation
BR112013004829A2 (pt) composição de agente de dispersão de produto químico agrícola, composição química agrícola, método para produzir um produto agrícola, método para aumentar eficácia em um produto químico agrícola, e uso da composição de agente de dispersão de produto químico agrícola.
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
DOP2010000331A (es) Formulacion de medicamento solida con liberacion retardada
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
WO2013104892A8 (en) Application of high dose compounds via inhalation
DOP2014000269A (es) Nueva dosificación y formulación
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
BR112013019924A2 (pt) composições para cuidado oral
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
MX2016008729A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
BR112013027488A2 (pt) Combinações de substâncias ativas e formulações cosméticas

Legal Events

Date Code Title Description
FC Refusal